Insulin resistance, a characteristic feature of type 2 diabetes, is associated with central obesity, hypertension, dyslipidemia, and cardiovascular disease (and death) (1). The mechanism of insulin resistance is complex and largely unknown. Both in animals and in humans, however, insulin resistance can be induced by lipid infusion. In a recent issue of the JCI, Kim and colleagues presented new data on the mechanisms responsible for the induction of insulin resistance by lipids. In an elegant set of experiments, they show that activation of IKK-β is important in fat-induced insulin (2). High-dose salicylate prevents the fat-induced defects in insulin signaling. Based on these findings, the authors suggest that “salicylates represent a potentially novel class of therapeutic agents for type 2 diabetes” (2).
Although the carefully performed study by Kim et al. provides new insight into the mechanisms of fat-induced insulin resistance, we would like to caution against the preliminary conclusion concerning beneficial effects of salicylates on insulin resistance. First of all, in contrast to the findings of Kim et al. in the triglyceride (TG) infusion model in the rat, earlier studies in human volunteers using hyperglycemic clamp techniques reported increased insulin resistance by salicylate compounds (3, 4). These findings suggest that the effects of salicylates may depend on the experimental model, and possibly on the species studied.
There are also strong theoretical arguments that salicylates have deleterious effects on insulin resistance. Similar to TGs (or fatty acids), the proinflammatory cytokine TNF-α synthesized by adipocytes is a central factor in the pathogenesis of insulin resistance (5). As underlined also by Kim et al., there is significant overlap between the intracellular events induced by fatty acids and TNF in insulin-sensitive tissues: both activate IKK-β and decrease IRS-1 tyrosine phosphorylation, and both increase intracellular ceramide concentrations, which leads to inhibition of Akt/protein kinase B activation and impaired GLUT-4 translocation (these relationships are outlined in Figure 1) (6–8). The effects of salicylates on TNF-induced insulin resistance are completely opposite to those reported by Kim and colleagues on fat-induced insulin resistance. TNF induces the synthesis of prostaglandins (PGs), which function as a negative feedback mechanism by inhibiting the upstream TNF production (9). We and others have shown in healthy volunteers that administration of aspirin or indomethacin, both strong inhibitors of PG synthesis, enhances TNF production capacity at least twofold (10, 11), which can negatively affect insulin sensitivity. In addition, PGs stimulate synthesis of leptin, an adipocytokine known to decrease insulin resistance through improvement of IRS-1−associated phosphatidylinositol (PI) 3-kinase activity (12, 13). Although not yet experimentally tested, inhibition of PG synthesis by salicylate compounds may also negatively influence insulin sensitivity by inhibition of leptin release. Thus, aspirin could increase insulin resistance through at least two mechanisms mediated by the inhibition of PG synthesis, namely the upregulation of TNF synthesis and the inhibition of leptin release (Figure 1). There are other important endogenous factors modulating the resistance to insulin: adiponectin reverses insulin resistance, possibly in part by inhibition of TNF synthesis, whereas resistin impairs glucose tolerance and insulin action (12, 14). The influence of salicylates on the modulation of these proteins is not known.
In conclusion, the influence of salicylate compounds on insulin sensitivity is multifactorial and involves both beneficial and deleterious effects. This should not preclude patients from taking low-dose aspirin to prevent cardiovascular disease (15), but more basal and clinical studies are needed before recommending higher dosages of salicylates for the treatment of type 2 diabetes itself.
References
- 1.Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121–131. doi: 10.1146/annurev.me.44.020193.001005. [DOI] [PubMed] [Google Scholar]
- 2.Kim JK, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437−446. doi: 10.1172/JCI11559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab. 1983;57:1102–1106. doi: 10.1210/jcem-57-6-1102. [DOI] [PubMed] [Google Scholar]
- 4.Giugliano D, Sacca L, Scognamiglio G, Ungaro B, Torella R. Influence of acetylsalicylic acid on glucose turnover in normal man. Diabetes Metab. 1982;8:279–282. [PubMed] [Google Scholar]
- 5.Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997;389:610–614. doi: 10.1038/39335. [DOI] [PubMed] [Google Scholar]
- 6.Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–176. doi: 10.1172/JCI10583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107:119–125. doi: 10.1055/s-0029-1212086. [DOI] [PubMed] [Google Scholar]
- 8.Kanety H, Hemi R, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem. 1996;271:9895–9897. doi: 10.1074/jbc.271.17.9895. [DOI] [PubMed] [Google Scholar]
- 9.Renz H, Gong J-H, Schmidt A, Nain M, Gemsa D. Release of tumor necrosis factor-α from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol. 1988;141:2388–2393. [PubMed] [Google Scholar]
- 10.Endres S, Whitaker RED, Ghorbani R, Meydani SN, Dinarello CA. Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1β and of tumour necrosis factor-α ex vivo. Immunology. 1996;87:264–270. doi: 10.1046/j.1365-2567.1996.472535.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Netea MG, Puren AJ, Dinarello CA. A short course of oral aspirin increases IL-18-induced interferon-gamma production in whole-blood cultures. Eur Cytokine Netw. 2000;11:379–382. [PubMed] [Google Scholar]
- 12.Yamauchi T, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946. doi: 10.1038/90984. [DOI] [PubMed] [Google Scholar]
- 13.Kim Y-B, Uotani S, Pierroz DD, Flier JS, Kahn BB. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. Endocrinology. 2000;141:2328–2339. doi: 10.1210/endo.141.7.7536. [DOI] [PubMed] [Google Scholar]
- 14.Steppan CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312. doi: 10.1038/35053000. [DOI] [PubMed] [Google Scholar]
- 15.Rolka DB, Fagot-Campagna A, Venkat Narayan KM. Aspirin use among adults with diabetes. Estimates from the Third National Health and Nutrition Examination. Diabetes Care. 2001;24:197–201. doi: 10.2337/diacare.24.2.197. [DOI] [PubMed] [Google Scholar]